A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia
Latest Information Update: 14 Oct 2024
At a glance
- Drugs PP 405 (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors Pelage Pharmaceuticals
- 09 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2024 Status changed from not yet recruiting to recruiting.
- 26 Apr 2024 Status changed from planning to not yet recruiting.